explore -WSS

explore

author：focus 2025-09-27 09:46:36 - browse：49

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

WSS

Slovenia has suffered its worst

Obesity drugs seen as possible treatment for liver disease MASH

Pennsylvania man bitten on the head by bear during attack in his garage

Alabama IVF ruling threatens families facing fatal genetic disease

Medicare inequities exacerbate Puerto Rico’s health disparities

Many breast cancer patients receive more radiation than needed

Wikipedia

explore

knowledge

Cancer drug shortages should be causing more outrage

Tuberculosis patients need more than just free medication

Novavax promises a turnaround & Lilly roils the obesity market

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Trump demands the U.S. pay no more for drugs than other countries … again

It was time to plan for my old age. If only I could stop crying

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New documents shed light on MD Anderson Cancer Institute feud

Hepatitis C has a cure — but many Americans still lack access to it

Tuberculosis patients need more than just free medication

Wikipedia

Antivenom research: Lessons from HIV applied in search for universal antidote

Failure, not just success, should guide future doctors

Trump used to be more articulate. What could explain the change?

Failure, not just success, should guide future doctors

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

explore

explore

knowledge